- April 19th. 2024Kyoto Drug Discovery & Development Doses First Subject in its US Phase 2 Trial of
KUS121 in Central Retinal Artery Occlusion (CRAO) - December 22nd. 2023KUS121 Phase 2 Study Registered in ClinicalTrials.gov
- November 10th. 2023Notice of IND Clearance by U.S. FDA Enabling Phase 2 Initiation of KUS121
for the treatment of Central Retinal Artery Occlusion (CRAO) - October 10th. 2023Notice of the Completion of Investigational New Drug Application for the treatment of
Central Retinal Artery Occlusion (CRAO) in the United States - April 1st. 2023Notice Concerning the Adoption of "Drug Discovery Support Promotion Project -
Pre-designation Commercialization Support Project for Orphan Drugs" - May 6th. 2022KUS121 receives Orphan Drug Designation from the US FDA
- April 28th. 2022Kyoto Drug Discovery & Development successfully concludes a pre-IND meeting with FDA
- August 23rd. 2017KDDD released this HP (English version).
The disclosure of information on medical drug development products in the news on the website of the Kyoto Drug Discovery & Development is not for the purpose of promotion, advertising, medical advice, etc.
KDDD (Kyoto Drug Discovery and Development Co., Ltd.) is a spin-off company from Kyoto University. Our project is based on a result of research by Department of Ophthalmology Kyoto University and Graduate School of Biostudies.
We sincerely aim to develop an innovative agent effective for various INCURABLE or INTRACTABLE eye diseases, especially CRAO, Retinal Pigmentosa, AMD and Glaucoma.